Shree ganesh bio-tech (India) Limited announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on January 29, 2026, at the company's registered office in Kolkata.

Quarterly Financial Performance

The company's financial performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations declined significantly while the company maintained profitability during the quarter.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Shree Ganesh Bio-Tech (India) Limited reported revenue from operations of ₹284.92 lakh compared to ₹1,995.18 lakh in the corresponding period of the previous year. The company achieved a net profit after tax of ₹66.34 lakh for the nine-month period, compared to ₹133.29 lakh in the previous year.

Cost Structure and Expenses

The company's cost structure showed significant changes during the quarter. Cost of materials consumed was ₹66.08 lakh in Q3FY26 compared to ₹1,375.91 lakh in Q3FY25. Employee benefit expenses increased to ₹7.35 lakh from ₹6.23 lakh in the corresponding quarter of the previous year.

Key Financial Highlights

The company maintained its paid-up equity share capital at ₹3,986.24 lakh with a face value of ₹1.00 per share. Basic and diluted earnings per share for Q3FY26 stood at ₹0.01, compared to ₹0.02 in Q3FY25. For the nine-month period, both basic and diluted earnings per share were ₹0.02.

Board Meeting Details

The Board of Directors meeting commenced at 3:30 PM and concluded at 4:00 PM on January 29, 2026. The unaudited financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors. The statutory auditors conducted a limited review of the results, which were prepared in accordance with Indian Accounting Standards.

Shree Ganesh Bio-Tech (India) Limited , a company operating in the biotech sector, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company has shown a decrease in both revenue and profitability compared to the previous year.

Financial Highlights

Key Observations

Revenue Performance

The company's revenue from operations for Q2 FY2026 stood at Rs. 76.74 lakhs, showing a significant decrease of 61.32% compared to Rs. 198.40 lakhs in the same quarter of the previous year. For the half-year, revenue reached Rs. 215.10 lakhs, down 61.17% from Rs. 554.01 lakhs in H1 FY2025.

Profitability

Shree Ganesh Bio-Tech reported a profit before tax of Rs. 1.41 lakhs for Q2 FY2026, a sharp decline of 95.64% from Rs. 32.34 lakhs in Q2 FY2025. For the half-year ended September 30, 2025, profit before tax was Rs. 34.11 lakhs, compared to Rs. 56.12 lakhs in the corresponding period of the previous year, indicating a 39.22% decrease in profitability.

Other Income

The company's other income for Q2 FY2026 increased to Rs. 41.01 lakhs from Rs. 30.29 lakhs in Q2 FY2025, helping to partially offset the decline in operational revenue.

Expenses

The cost of material consumed for H1 FY2026 was Rs. 223.72 lakhs, significantly lower than Rs. 535.74 lakhs in H1 FY2025, aligning with the reduced revenue.

Balance Sheet Position

As of September 30, 2025, the company's total assets stood at Rs. 6,513.75 lakhs, with a strong equity base of Rs. 6,359.70 lakhs.

The Board of Directors approved these financial results at their meeting held on November 8, 2025. The company operates in a single business segment, as stated in the notes to the financial statements.

Shree Ganesh Bio-Tech's performance in the second quarter and first half of FY2026 reflects significant challenges in revenue generation and profitability compared to the previous year. However, the company maintains a stable financial position with a strong equity base. Investors and stakeholders may want to monitor the company's strategies for addressing the revenue decline and improving profitability in the coming quarters.